Literature DB >> 24577241

Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.

Abigail T Fahim1, Naheed W Khan1, Mark W Johnson1.   

Abstract

IMPORTANCE Ocriplasmin cleaves fibronectin and laminin, components of the vitreous gel, and is used as a pharmacologic treatment for vitreomacular traction. Laminin is also found throughout multiple retinal layers. Ocriplasmin injection may lead to acute panretinal dysfunction in some eyes, but the mechanism of this toxic reaction has not been described. OBSERVATIONS We evaluated a 63-year-old woman demonstrating acute panretinal dysfunction after intravitreous ocriplasmin injection for a small macular hole with vitreomacular adhesion. Findings included visual acuity loss, visual field constriction, pupillary abnormalities, attenuated retinal arteries, loss of outer retinal signals on spectral-domain optical coherence tomography, and severely reduced electroretinography responses. B-waves were reduced more than A-waves were, suggesting postreceptoral dysfunction and decreased photoreceptor activity. CONCLUSIONS AND RELEVANCE Retinal dysfunction associated with intravitreous ocriplasmin injection is not limited to the macular region and seems to involve the entire retina. Enzymatic cleavage of intraretinal laminin is a biologically plausible mechanism for acute ocriplasmin retinal toxic effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577241     DOI: 10.1001/jamaophthalmol.2013.8142

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  30 in total

1.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Authors:  M Maier; S Abraham; C Frank; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

2.  [Unclear retinopathy after intravitreal injection of ocriplasmin].

Authors:  S Abraham; K Wand; S Stumpfe; N Feucht; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

3.  Acute ocriplasmin retinopathy.

Authors:  Mark W Johnson; Abigail T Fahim; Rajesh C Rao
Journal:  Retina       Date:  2015-06       Impact factor: 4.256

4.  Three-dimensional spectral domain optical coherence tomography in vitreomacular traction.

Authors:  Sandeep Saxena; Carsten H Meyer; Levent Akduman
Journal:  BMJ Case Rep       Date:  2014-06-17

5.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

6.  Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.

Authors:  D H W Steel; C Parkes; V T Papastavrou; P J Avery; I A El-Ghrably; M S Habib; M T Sandinha; J Smith; K P Stannard; D Vaideanu-Collins; R J Hillier
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

7.  Real world outcomes of ocriplasmin use by members of the British and Eire Association of Vitreoretinal Surgeons.

Authors:  R J Haynes; D Yorston; D A H Laidlaw; J Keller; D H W Steel
Journal:  Eye (Lond)       Date:  2016-09-02       Impact factor: 3.775

8.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

Review 9.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

Review 10.  Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.

Authors:  Yuji Itoh; Peter K Kaiser; Rishi P Singh; Sunil K Srivastava; Justis P Ehlers
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.